All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 700+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Servier Pharmaceuticals’ 2021 $1.8B Agios Pharmaceuticals oncology division acquisition pays off with FDA approval for cancer med
Small molecule, astrocytoma, oligodendroglioma, cancer - Read more

Exelixis’ neuroendocrine sNDA accepted by FDA, target date Apr 3 2025
Small molecule, pancreatic neuroendocrine tumors, cancer - Read more

George Medicines submits NDA to FDA for triple combo hypertension med
Small molecule, hypertension - Read more

THE GOOD
Business Development

Recursion signs $30M licensing deal with Roche, Genentech
Drug development, neuroscience phenomap, in silico - Read more

Agios Pharmaceuticals to receive $1.1B milestone payment from Servier Pharmaceuticals, Royalty Pharma after cancer med FDA approval
Small molecule, astrocytoma, oligodendroglioma, cancer - Read more

Seres Therapeutics sells VOWST business to Nestlé Health Science
Microbiome treatment, clostridioides difficile infection - Read more

THE GOOD
Clinical Trials

Levicept’s ex-Pfizer osteoarthritis med posts positive Ph2 results
Fusion protein, osteoarthritis, chronic pain - Read more

Lupin’s Lucentis biosimilar successfully completes Ph3 trials
Monoclonal antibody fragment, biosimilar, wet age-related macular degeneration (AMD) - Read more

Genentech touts diversity recruitment win at their Site Alliance clinical trial sites
Diversity in clinical trials, clinical trial recruiting, CRO - Read more 

THE GOOD
Company Launches

Symbiotic Capital launches with $600M, credit firm business model for life science
Credit agreements, life science financing, fundraising - Read more

Red Queen Biotech launches with $55M, backed by BARDA and Apple Tree Partners
Recombinant polypeptide, Infectious disease, antiviral, viral infection, COVID-19 - Read more 

THE GOOD
Earnings & Finances

Krystal Biotech posts rapid sales growth for their topical gene therapy
Topical gene therapy, dystrophic epidermolysis bullosa - Read more

Bayer showcases their “modest” Q2 performance - Read more

Consumer health brand Hims & Hers rides the weight loss wave to dizzying revenue heights
Consumer health, telehealth, virtual health, weight loss - Read more

THE GOOD
Fundraises

TPG adds $580M to Life Science Innovations fund
Asset management, life science investment, biotech investment - Read more

Terumo established Terumo Ventures VC division with $75M ready to invest
Venture capital, early-stage companies, cardiovascular, chronic disease, digital therapeutics - Read more

Shinobi Therapeutics extends Series A to $119M, secures $59M grant from the Japan Agency for Medical Research and Development
Induced pluripotent stem cells (iPS cells, iPSCs) derived therapies, off-the-shelf cell therapy, allogeneic cell therapy - Read more

Nilo Therapeutics $101M Series A
Autoimmune and inflammatory disease - Read more [Paywall]

Nob Hill Therapeutics $3M Series A
Medical device, nebulizer, lung-related disease - Read more

NeuroTherapia $12.3M Series B
Small molecule, neuro-inflammatory, Alzheimer’s disease - Read more

Tenax Therapeutics $100M oversubscribed private placement
Small molecule, pulmonary arterial hypertension, cardiovascular disease - Read more

Artax Biopharma $8M convertible debt financing
Small molecule, T Cell-driven autoimmune diseases, psoriasis - Read more

Release Therapeutics CHF 3.3M ($3.8M) Seed raise
Enzyme replacement therapy, medical device, metachromatic leukodystrophy, rare disease - Read more

THE GOOD
Investments

Pfizer invests AU$150M ($98 million) in Melbourne manufacturing site
Antimicrobial resistance, drug development, manufacturing - Read more

THE GOOD
Lawsuits

GSK found not liable in another Zantac case
Small molecule, heartburn, cancer - Read more

THE GOOD
Partnerships

Merck & Co., Daiichi Sankyo sign deal to jointly develop, commercialize T-cell engager bispecific
Bispecific antibody, T-cell engager, lung cancer - Read more

Sangamo signs licensing partnership for their “zinc finger” tech to Genentech (Roche)
Zinc finger protein, AAV capsid, Alzheimer’s disease - Read more

Eisai, SEED Therapeutics protein degrader development partnership, up to $1.5B value
Protein degrader, molecular glue, biomarker-driven cancer, Alzheimer’s disease - Read more

Denmark’s BioInnovation Institute collab with MIT and University of North Carolina in support of Bio Studio company creation program
Life science company creation, academic spin-out - Read more

Santen Pharmaceutical, Cloudbreak Pharma licensing agreement for ophthalmic small molecule
Small molecule, ophthalmology, pterygium - Read more

Neurobo Pharmaceuticals, Dong-A ST, Immunoforge sign long-acting, once-monthly obesity med research pact
Peptide, GLP1R, obesity, weight loss - Read more

THE GOOD
Product Launches

Zoi Capital has a fancy new Health AI investment assessment tool
AI, healthcare investment - Read more

THE GOOD
Strategic Plans

Bayer continues pushing key products to drive revenue growth
Small molecule, anticoagulant, prostrate cancer, fusion protein, wet age-related macular degeneration (AMD) - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Ultimovacs head & neck cancer vaccine takes a fat L in Ph2
Cancer vaccine, head & neck carcinoma - Read more

BioCryst cuts clinical asset after disappointing clinical activity, no partners interested in evaluating higher doses
Small molecule, complement-mediated disease, paroxysmal nocturnal hemoglobinuria - Read more

THE BAD
Company Shutdown

Aerium Therapeutics shuts down
Antibody, COVID-19, pandemic response - Read more [Paywall]

THE BAD
Earnings & Finances

Bicycle Therapeutics catches analyst flack after recent earnings report
Protein, small molecule linker, cancer - Read more

Amgen’s revenue beat analysts estimates but misses on EPS, causing stock to slip - Read more

THE BAD
Lawsuits

Novo Nordisk continues compounding hunt, serves more lawsuits against GLP-1 compounding pharmacies
GLP-1, obesity, weight loss, drug compounding - Read more [Paywall]

THE BAD
Layoffs

Bayer’s spills (metaphorical) managerial blood with 3200 full-time cuts in 2024 H1 - Read more 

THE BAD
Strategic Plans

BioMarin Pharmaceutical lowers Roctavian ambitions, restricts commercial market to US, Germany, and Italy
AAV gene therapy, hemophilia A - Read more

THE UGLY
Lawsuits

Novartis, Viatris sued by Henrietta Lacks estate
HeLa cell line, immortal cell line - Read more

THE UGLY
Patient Access

Roche is “jerking families around” regarding shuttered rare disease trial
Small molecule, dup15q syndrome - Read more [Paywall]

THE UGLY
Warnings Letters, Form 483s

Aurobindo’s Eugia unit hit with FDA escalation, “Official Action Indicated” notice
Manufacturing, microbial contamination concerns - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.